These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2140863)

  • 41. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
    Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
    Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).
    Smith JE; Lawless DC; Green MH; Moon RC
    J Nutr; 1992 Oct; 122(10):1999-2009. PubMed ID: 1388202
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Night blindness following low-dose isotretinoin.
    Halpagi P; Grigg J; Klistorner A; Damian DL
    J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):893-4. PubMed ID: 18031494
    [No Abstract]   [Full Text] [Related]  

  • 44. Acquired unilateral loss of dark adaptation.
    Kelsey JH; Arden GB
    Br J Ophthalmol; 1971 Jan; 55(1):38-43. PubMed ID: 5313627
    [No Abstract]   [Full Text] [Related]  

  • 45. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
    Swanson BN; Zaharevitz DW; Sporn MB
    Drug Metab Dispos; 1980; 8(3):168-72. PubMed ID: 6104581
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzymatic hydrolysis of retinamides.
    Shih TW; Shealy YF; Hill DL
    Drug Metab Dispos; 1988; 16(3):337-40. PubMed ID: 2900722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Unclear retinopathy after intravitreal injection of ocriplasmin].
    Abraham S; Wand K; Stumpfe S; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2016 Feb; 113(2):156-9. PubMed ID: 26205745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genotype and phenotype of 101 dutch patients with congenital stationary night blindness.
    Bijveld MM; Florijn RJ; Bergen AA; van den Born LI; Kamermans M; Prick L; Riemslag FC; van Schooneveld MJ; Kappers AM; van Genderen MM
    Ophthalmology; 2013 Oct; 120(10):2072-81. PubMed ID: 23714322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Herelopia and ocular alterations by deficiency in Greece during the years 1941-45].
    SPYRATOS S
    Ann Ocul (Paris); 1949 Sep; 182(9):672-85. PubMed ID: 18143901
    [No Abstract]   [Full Text] [Related]  

  • 51. THE TOXIC EFFECTS OF ETHYLHYDROCUPREIN ON THE EYE.
    Oliver GH
    Br Med J; 1916 Apr; 1(2886):580-1. PubMed ID: 20768098
    [No Abstract]   [Full Text] [Related]  

  • 52. Total rod ERG suppression with high dose compassionate Fenretinide usage.
    Marmor MF; Jain A; Moshfeghi D
    Doc Ophthalmol; 2008 Nov; 117(3):257-61. PubMed ID: 18523815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
    Puduvalli VK; Yung WK; Hess KR; Kuhn JG; Groves MD; Levin VA; Zwiebel J; Chang SM; Cloughesy TF; Junck L; Wen P; Lieberman F; Conrad CA; Gilbert MR; Meyers CA; Liu V; Mehta MP; Nicholas MK; Prados M;
    J Clin Oncol; 2004 Nov; 22(21):4282-9. PubMed ID: 15514370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Electroretinographic findings in subjects after administration of fenretinide.
    Krzeminski R; Zwas F; Esper P; Pienta K
    Doc Ophthalmol; 1995-1996; 91(4):299-309. PubMed ID: 8899300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risks and benefits of retinoids in the chemoprevention of cancer.
    de Palo G; Formelli F
    Drug Saf; 1995 Oct; 13(4):245-56. PubMed ID: 8573297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular toxic effects of fenretinide.
    Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
    J Natl Cancer Inst; 1990 Jun; 82(12):1063. PubMed ID: 2140863
    [No Abstract]   [Full Text] [Related]  

  • 57. Visual and cutaneous toxicity which occurs during N-(4-hydroxyphenyl) retinamide therapy for psoriasis.
    Kingston TP; Lowe NJ; Winston J; Heckenlively J
    Clin Exp Dermatol; 1986 Nov; 11(6):624-7. PubMed ID: 2959409
    [No Abstract]   [Full Text] [Related]  

  • 58. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
    Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
    Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormal retinal function associated with fenretinide, a synthetic retinoid.
    Kaiser-Kupfer MI; Peck GL; Caruso RC; Jaffe MJ; DiGiovanna JJ; Gross EG
    Arch Ophthalmol; 1986 Jan; 104(1):69-70. PubMed ID: 2935125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retinoids and the eye.
    Gross EG; Helfgott MA
    Dermatol Clin; 1992 Jul; 10(3):521-31. PubMed ID: 1617811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.